Robinhood Markets, Inc. vs Heron Therapeutics Inc — how do they compare? Robinhood Markets, Inc. trades at $95.4 (market cap $84.86B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: Robinhood Markets, Inc. is far larger — about 1380.5× Heron Therapeutics Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HOOD | HRTX | |
|---|---|---|
Market Cap | $84.86B | $61.47M |
Sector | Technology | Health |
52-Week High | $152.46 | $1.49 |
52-Week Low | $65.16 | $0.32 |
Enterprise Value | $91.40B | $168.21M |
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $95.19, up 0.71% on the day, with the stock showing strong fundamental momentum despite a bearish technical signal. The company reported impressive 2025 results with $4.47B revenue and $1.88B net income, representing 42% net margins. Recent Q2 2026 earnings beat expectations with $0.62 EPS versus $0.44 expected, though technical indicators show resistance near $95-97 levels with RSI suggesting potential overbought conditions.
HOOD presents a compelling growth story with 73% analyst buy ratings and a $123.46 consensus price target representing 30% upside potential. Key opportunities include international expansion and product diversification beyond crypto, while risks involve competitive pressures and market volatility sensitivity. The company's transition to profitability and strong cash flow generation support long-term bullish thesis despite near-term technical headwinds.
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →